Fig. 7.

Modulation of TRPV1 decreases apoptosis and COLA1A level in PCLS of IPF patients. A PCLS from explanted IPF patient lungs were treated with either DMSO or CPS with the indicated concentrations for 8 h, followed by immunoblot analysis for PACS2, cleaved caspase 3 and GAPDH. B-D Quantification of PACS2 (B) and cl.caspase3 (C) protein levels is shown. Relative protein amounts were normalized to GAPDH and their mean value in DMSO-treated PCLS was set as one. D Immunofluorescence staining for cl.caspase 3 (red) in AECII (ABCA3, green) on IPF PCLS upon Veh, CPS or Nin treatment for 8 h. Nuclei were stained with DAPI (blue), scale bar = 60 µm. E Fluorescence intensity of cleaved caspase 3 in ABCA3-positive cells was quantified using ImageJ, and its intensity in DMSO-treated cells was set as one. F Immunofluorescence staining for COLA1A on IPF PCLS upon Veh, CPS or Nin treatment for 8 h. Nuclei were stained with DAPI (blue), scale bar = 60 µm. H Fluorescence intensity of COLA1A was quantified using ImageJ, and its intensity in DMSO-treated cells was set as one. Stainings and analysis were performed in PCLS performed from three IPF patients and significance is indicated as: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001